hVIVO Clinches Major Contract for RSV Challenge Trials

Open Orphan Plc (GB:HVO) has released an update.

hVIVO plc has secured an £11.5 million contract with a leading pharmaceutical company to conduct a Phase 2a trial using its RSV Human Challenge Study Model. This collaboration underscores hVIVO’s reputation for delivering efficient and cost-effective human challenge trials, which are pivotal in accelerating drug development. With these trials, hVIVO continues to play a crucial role in addressing unmet medical needs in infectious and respiratory diseases.

For further insights into GB:HVO stock, check out TipRanks’ Stock Analysis page.